Stay updated on Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial
Sign up to get notified when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.
Latest updates to the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has been updated to version v2.10.0, indicating a new release with potentially significant changes, while the previous version v2.9.7 has been removed.SummaryDifference0.3%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more' has been updated to 'Show less'. Additionally, the Last Update Posted has been revised to 2024-06-21, and the Revision has been updated to v2.9.1. The study details now include a phase II open-label study of nivolumab combined with ipilimumab and bicalutamide for HER2-negative metastatic or unresectable breast cancer.SummaryDifference21%
Stay in the know with updates to Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.